09.10.2015 • News

SABIC Realigns Business Unit Structure

Following a strategic review, Saudi Arabian petrochemicals group SABIC has announced a new corporate organization that it said is designed to address changes in the market landscape and the need to drive technology and innovation.

To meet challenges going forward, SABIC said it is realigning its existing portfolio while at the same time investing in innovation for future growth.

The Saudi group’s Innovative Plastics Strategic Business Unit (SBU) is being phased out and its products grouped under the Chemicals and Polymers SBUs. The remaining Innovative Plastics’ solutions will be absorbed by a newly created SBU, Specialties. The Performance Chemicals SBU, whose portfolio was reallocated earlier, also will cease to exist.

Yousef Abdullah Al-Benyan, SABIC’s acting CEO, said the reorganization will focus the group’s resources more intensively on the needs of each line, enhancing customer intimacy with more focused solutions provision.

One of the drivers of the changes is said to be the differing technology priorities of the group’s commodity and specialty businesses.

While in future the commodity lines will depend heavily on innovations around advancing feedstock technology, SABIC said specialty products face separate technology challenges, including the need to seek out technology acquisitions and partnerships or joint ventures. It did not comment on any specific plans.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.